



UNITED STATES PATENT AND TRADEMARK OFFICE

RD
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/592,032	06/12/2000	Flemming Junker	3500.244-US	5100
23650	7590	07/15/2004	EXAMINER	
NOVO NORDISK PHARMACEUTICALS, INC 100 COLLEGE ROAD WEST PRINCETON, NJ 08540				LIU, SAMUEL W
		ART UNIT		PAPER NUMBER
		1653		

DATE MAILED: 07/15/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Supplemental Notice of Allowability	Application No. 09/592,032 Examiner Samuel W Liu	Applicant(s) JUNKER ET AL. Art Unit 1653
--	---	---

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. This communication is responsive to 9-11-03 and 12-9-02.
2. The allowed claim(s) is/are 1-9, 11-15, 18, 20-24 and 28.
3. The drawings filed on 12 June 2000 are accepted by the Examiner.
4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some* c) None of the:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

5. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.
 - (a) The translation of the foreign language provisional application has been received.
6. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. **THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.**

7. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
8. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) hereto or 2) to Paper No. _____.
 - (b) including changes required by the proposed drawing correction filed _____, which has been approved by the Examiner.
 - (c) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No. _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the margin according to 37 CFR 1.121(d).

9. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1 <input type="checkbox"/> Notice of References Cited (PTO-892)	5 <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
2 <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	6 <input checked="" type="checkbox"/> Interview Summary (PTO-413), Paper No. <u>1-26-04</u> .
3 <input checked="" type="checkbox"/> Information Disclosure Statements (PTO-1449 or PTO/SB/08), Paper No. <u>12-9-02</u>	7 <input checked="" type="checkbox"/> Examiner's Amendment/Comment
4 <input type="checkbox"/> Examiner's Comment Regarding Requirement for Deposit of Biological Material	8 <input type="checkbox"/> Examiner's Statement of Reasons for Allowance
	9 <input type="checkbox"/> Other .

DETAILED ACTION

The terminal disclaimer filed on 11 September 2002 has been reviewed and is accepted.

This Office action is in response to (i) applicants' amendments filed 11 September 2003, which amends claims 14, 20-22, and cancels claims 16-17 and 25-27, (ii) applicants' amendment filed 9 December 2002, which cancels claims 10 and 19, adds claims 20-27, and amends claims 1-3, 6-8, 11-13, 15 and 17-18; and (iii) Applicants' request for extension of time of three months (filed 11 September 2003). The papers indicated above have been entered. Note that claims 15-18 are rejoined with Group I, claims 1-14 and 19-27, which is stated in the Office action mailed 4 June 2002. Thus, the pending claims 1-9, 11-15, 18, 20-24 and 28 are examined in this Office action.

SPECIFICATION

Note that the specification is objected to because the specification of the instant application contains no description of the drawing shown at page 22 of the applicants' letter, filed 12 June 2000. A brief description for the drawing is required.

EXAMINER'S AMENDMENT

An Examiner's Amendment to the record appears below. Should the change and/or additions be unacceptable to Applicant, an amendment may be filed as provided by 37 C.F.R. § 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than payment of the Issue Fee.

Authorization for this examiner's amendment was given in a telephonic interview with Paula A. Borden on January 26, 2004.

Amendments to the claims:

Claim 1 (*amended*): Change "cations of inorganic or organic nature" to "inorganic or organic cations".

Claim 3 (*amended*): After "consisting of short", change "chained" to "chain".

Claim 7 (*amended*): After "0.1 to 30%", add "v/v".

Claim 15 (amended): Before “cation crystal”, add “Isolated”.

Claim 18 (amended): After “A pharmaceutical preparation,” delete comma “,” and change “characterized in that it contains” to “comprising”.

Amendments to the specification:

In page 1, line 5, after “(growth) hormone”, add “(GH)”.

In page 3, line 6, change “Zn” to “zinc”.


Conclusion: Claims 1-9, 11-15, 18, 20-24 and 28 are allowable over the art of record.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Samuel Wei Liu, Ph.D. whose telephone number is (571) 272-0949. The Examiner can normally be reached daily except alternate Fridays from 8:30 A.M. to 5:30 P.M. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Christopher Low, can be reached at (571) 272-0951. The official fax phone number for Technology Center 1600 is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.

SWL

Samuel W. Liu, Ph.D.
January 26, 2004



Jon P. Weber, Ph.D.
Primary Examiner